Attached files
| file | filename |
|---|---|
| 8-K - 8-K - DYNAVAX TECHNOLOGIES CORP | rrd295339.htm |
Exhibit 99.1
DYNAVAX
DYNAVAX TECHNOLOGIES
2929 Seventh Street, Suite 100
Berkeley, CA 94710
|
Contact: |
||
|
Michael Ostrach |
||
|
Vice President and Chief Business Officer |
||
|
510-665-7257 |
||
|
mostrach@dynavax.com |
Dynavax Reports Phase 1B Safety and Immunogenicity Results for HEPATITIS B THERAPY CANDIDATE
BERKELEY, CA - December 23, 2010 - Dynavax Technologies Corporation (Nasdaq: DVAX) today reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine. The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection. The Phase 1b data showed:
No conclusions regarding the potential clinical impact of the therapy could be reached in this small study. Dynavax's treatment approach combines both the surface and core hepatitis B virus (HBV) antigens with ISCOMATRIXÒ adjuvant originally entered into development by Rhein Biotech prior to its acquisition by Dynavax in 2006. The candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit, www.dynavax.com.
ISCOMATRIX® is a registered trademark of CSL Behring
# # #